Klebsiella pneumoniae is an opportunistic pathogen which causes pneumoniae, urinary tract infections and septicemia in immunocompromised patients. Hospital outbreaks of multidrug-resistant K. pneumoniae, especially those in neonatal wards, are often caused by strains producing the extended-spectrum-beta-lactamases (ESBLs). An immunoproteome based approach was developed to identify candidate antigens of K. pneumoniae for vaccine development. Sera from patients with acute K. pneumoniae infections (n = 55) and a control group of sera from healthy individuals (n = 15) were analyzed for reactivity by Western blot against ESBL K. pneumoniae outer membrane proteins separated by 2-DE. Twenty highly immunogenic protein spots were identified by immunoproteomic analysis. The immunogenic proteins that are most frequently recognized by positive K. pneumoniae sera were OmpA, OmpK36, FepA, OmpK17, OmpW, Colicin I receptor protein and three novel proteins. Two of the vaccine candidate genes, OmpA (Struve et al. Microbiology 2003, 149, 167-176) and FepA (Lai, Y. C. et al.. Infect Immun 2001, 69, 7140-7145), have recently been shown to be essential in colonization and infection in an in vivo mouse model. Hence, these two immunogenic proteins could serve as potential vaccine candidates.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pmic.200500214 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 mortality among solid organ transplant recipients and candidates before specific vaccine availability in Colombia.
J Infect Dev Ctries
December 2024
Infectious Diseases Research Group, School of Medicine, Universidad Nacional de Colombia (National University of Colombia), Bogotá, Colombia.
Introduction: Coronavirus disease 2019 (COVID-19) is a life-threatening disease that was declared a pandemic in March 2020. Organ transplant recipients are vulnerable to infection and complications from COVID-19. The objective of this study was to investigate the rates of infection, mortality, and case-fatality ratios (CFR) in solid organ transplant recipients and patients on the waiting list for organ allocation in the period prior to the availability of specific vaccines.
View Article and Find Full Text PDFGenetically attenuated parasites show promise as a next-generation malaria vaccine.
Trends Parasitol
January 2025
Department of Molecular Parasitology, Institute of Biology, Humboldt Universität zu Berlin, 10115 Berlin, Germany. Electronic address:
Metabolically active, genetically attenuated Plasmodium falciparum parasite lines are promising second-generation malaria vaccine candidates. Lamers et al. and Roozen et al.
View Article and Find Full Text PDFRecombinant probiotic Escherichia coli delivers the polymeric protein of swine influenza virus for protection.
Vet Microbiol
January 2025
College of Veterinary Medicine, Jilin Provincial Engineering Research Center of Animal Probiotics, Jilin Provincial Key Laboratory of Animal Microecology and Healthy Breeding, Engineering Research Center of Microecological Vaccines (Drugs) for Major Animal Diseases, Ministry of Education, Jilin Agricultural University, Changchun 130118, China. Electronic address:
Swine influenza virus invades the host through the respiratory mucosa, which severely restricts the development of the pig breeding industry. To construct monomeric and trimeric vaccines, we developed recombinant Escherichia coli Nissle 1917 (EcN) strains that express the receptor binding site (RBS) of the hemagglutinin (HA) antigen from H1N1 swine influenza virus. After the mucosal immunization of mice, we found that probiotics activated CD40 and CD86 in DCs and increased the levels of IL-4 and IFN-γ secretion by T cells.
View Article and Find Full Text PDFPotential therapeutics and vaccines: Current progress and challenges in developing antiviral treatments or vaccines for Oropouche virus.
Diagn Microbiol Infect Dis
January 2025
Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001 India. Electronic address:
Oropouche virus (OROV), an emerging arbovirus, poses a significant public health challenge in tropical and subtropical regions, with no licensed vaccines or antiviral therapies currently available. This review explores recent advancements in therapeutic strategies and vaccine development for OROV, focusing on molecular mechanisms of viral replication, identification of potential antiviral targets, and the role of immunotherapy in managing infections. Promising antiviral candidates, including ribavirin, mycophenolic acid, and interferon, have demonstrated efficacy in in vitro studies, offering a foundation for further investigation.
View Article and Find Full Text PDFA new vaccination approach for Salmonellosis employing a multi-epitope vaccine based on live microbial cell factory from Lactococcus lactis.
Poult Sci
January 2025
Department of Microbiology, Faculty of Basic Sciences, East Tehran Branch, Islamic Azad University, Tehran, Iran.
A major health and financial burden in the chicken sector is salmonella infection. It is difficult to create an oral vaccination that can provide strong intestinal mucosal immunity in birds, particularly cross-protection against several Salmonella serotypes. As a result, the poultry industry needs a powerful oral vaccination platform that uses live bacterial vectors to prevent various Salmonella serotypes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!